Program overview
Context
Indication: Non-Small Cell Lung Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: AstraZeneca
Osimertinib is flagged as timeline staleness signal because public records show timeline staleness, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Indication: Non-Small Cell Lung Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: AstraZeneca
Registry: 1/5
Timeline: 4/5
Recruitment burden: 3/5
Results availability: 0/5
Program risk: 4/5
https://clinicaltrials.gov/study/NCT03944772
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT03944772 | Low Signal (ACTIVE_NOT_RECRUITING) | stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal | long_recruitment_duration_signal | Low Signal | large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal |